Platelet-specific targets and novel anti-inflammatory agents acting against them represent a potential therapeutic approach for managing thrombo-inflammatory diseases.
Platelets, the cytoplasmic fragments of megakaryocytes, play a primary role in hemostasis. In addition, current evidence demonstrates the contribution of platelets in inflammation. Platelet-associated cell surface proteins (e.g. CD40L, P-selectin, GPVI and CLEC-2) and secretory molecules (e.g. PF4 and RANTES) regulate inflammatory response in various conditions, including cardio-cerebrovascular diseases, inflammatory bowel disease, rheumatoid arthritis and infection/sepsis. Anti-platelets and anti-inflammatory drugs have been shown to reduce the expression and/or function of these platelet-derived molecules, in association with the improved clinical outcomes in patients with inflammatory diseases. Moreover, the novel anti-inflammatory agents that act against platelet-specific targets have been being developed, which might be a potential therapeutic approach in thrombo-inflammatory diseases.
Wichaiyo et al. (Fri,) conducted a review in Inflammatory diseases. Anti-platelet and anti-inflammatory drugs targeting platelet-specific molecules was evaluated. Platelet-specific targets and novel anti-inflammatory agents acting against them represent a potential therapeutic approach for managing thrombo-inflammatory diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: